IDEAYA Biosciences, Inc. (IDYA)

From the record

IDEAYA Biosciences, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

IDEAYA Biosciences, Inc.'s 7 filed years say what it did: it rose in 3 of 5 years; the deepest fall was 86% from fiscal 2022 to fiscal 2024; net income was positive in 0 of 7 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, IDEAYA Biosciences, Inc. lost about 11 cents for every dollar of shareholders' money. Leverage: it owed about 8 cents per dollar of assets, and net share issuance: its share count grew 8.3% over the year (the filed statements).

From the record

IDEAYA Biosciences, Inc.'s standing among 315 graded names in its industry family: revenue of $219 million in fiscal 2025 ranks in the top 28% by size; a net margin of -52% ranks in the top 41%; revenue growth of 62.5% a year over the last 3 filed years ranks in the top 20% (its annual reports).

From the record

IDEAYA Biosciences, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Hata, Yujiro S (President and CEO, as filed), filing under that title since 2019-05-22, 7.5 years (top 27% of its family); the 14 officers and directors filing in the last fifteen months have been on the record a median of 4.8 years (bottom 32%); 4 officer or director changes were reported on Form 8-K since 2023-11-13, against the 14 people in charge now (top 28%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

IDEAYA Biosciences, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $114 million against no long-term debt tagged leaves 10.3% of its assets as net cash, bottom 26% of its family; cash from operations less capital spending is -33.6% of revenue (top 42%); research spending of 143.9% of revenue (top 45%) (its annual report).

From the record

IDEAYA Biosciences, Inc.'s growth drivers, from the filed years to fiscal 2025: the newest year grew 3031.8% (top 2%); research spending grew 52% a year (top 8%); capital spending grew -11.7% a year (top 48%) (its annual reports). IDEAYA Biosciences, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

IDEAYA Biosciences, Inc.'s newest year against its own record: revenue of $219 million in fiscal 2025 came in 8322.1% above the $3 million its prior three years' pace pointed to (top 2% of its family); net income of $114 million against a prior three-year average of $149 million (top 45%); a net margin of -52% against losses larger than its revenue before (top 13%) (its annual reports).